GE HealthCare: Soft Execution More Than Priced Accordingly
GE HealthCare's shares have declined to $60 following a weaker-than-expected Q1 and a reduction in full-year guidance, with organic growth at 2.9% and narrowed EBIT margin outlook. Despite these challenges, the stock is now trading at the lower end of its post-spin valuation range, with price-to-earnings multiples compressing to 12–13x. The market reaction may have overcorrected, potentially presenting a buying opportunity given the company's long-term fundamentals.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4896454-ge-healthcare-soft-execution-more-than-priced-accordingly"},"author":{"@type":"Person","name":"The Value…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
